Picture of Soleno Therapeutics logo

SLNO Soleno Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapNeutral

Annual cashflow statement for Soleno Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-30.8-24.6-30.9-24.1-39
Depreciation
Non-Cash Items8.94-5.512.332.089.16
Other Non-Cash Items
Changes in Working Capital2.52.98-1.15-0.7562.93
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-17.4-25.2-27.8-20.8-24.9
Capital Expenditures-0.021-0.007-0.022-0.0130
Purchase of Fixed Assets
Other Investing Cash Flow Items0.5490
Other Investing Cash Flow
Cash from Investing Activities0.528-0.007-0.022-0.0130
Financing Cash Flow Items-0.12-1.060
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities14.553.7-0.12814.1180
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-2.3728.5-27.9-6.7155